Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 11% – Here’s Why

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) shares traded up 11% on Thursday . The company traded as high as $8.43 and last traded at $8.35. 1,352,715 shares were traded during mid-day trading, a decline of 15% from the average session volume of 1,591,148 shares. The stock had previously closed at $7.52.

Wall Street Analyst Weigh In

AUPH has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.22 billion, a PE ratio of -24.26 and a beta of 1.45. The stock’s 50 day moving average price is $7.07 and its two-hundred day moving average price is $6.07.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its stake in shares of Aurinia Pharmaceuticals by 12.0% during the first quarter. BNP Paribas Financial Markets now owns 78,466 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 8,398 shares during the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth about $158,000. Nordea Investment Management AB grew its holdings in shares of Aurinia Pharmaceuticals by 51.7% during the first quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock worth $1,552,000 after buying an additional 105,100 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Aurinia Pharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 2,873 shares during the last quarter. Finally, Jupiter Asset Management Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 21.3% during the first quarter. Jupiter Asset Management Ltd. now owns 247,052 shares of the biotechnology company’s stock valued at $1,238,000 after buying an additional 43,366 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.